Advanced BioMedical Technologies, Inc.: 10-Q filed 2018-06-19
What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2018-06-19 (fiscal Q2 2018): 25 published measures, 71 facts as tagged in accession 0001493152-18-008900.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-06-19
- Fiscal period
- fiscal Q2 2018
- Accession
- 0001493152-18-008900 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 129,424 | USD | |
| At 2017-10-31 | 85,447 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | -5,635,868 | USD | |
| At 2017-10-31 | -4,995,027 | USD | |
| At 2016-10-31 | -4,362,295 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 13,485 | USD | |
| At 2017-10-31 | 7,463 | USD | |
| At 2017-04-30 | 35,872 | USD | |
| At 2016-10-31 | 6,559 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | -208,819 | USD | 89 |
| 2017-11-01 to 2018-04-30 | -431,362 | USD | 181 |
| 2016-11-01 to 2017-10-31 | -691,600 | USD | 365 |
| 2017-02-01 to 2017-04-30 | -183,335 | USD | 89 |
| 2016-11-01 to 2017-04-30 | -337,448 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-04-30 | -406,484 | USD | 181 |
| 2016-11-01 to 2017-04-30 | -190,673 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-04-30 | 5,256 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-04-30 | 450,439 | USD | 181 |
| 2016-11-01 to 2017-04-30 | 218,868 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-11-01 to 2018-04-30 | -38,110 | USD | 181 |
| 2016-11-01 to 2017-04-30 | 1,198 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | -8,110,660 | USD | |
| At 2017-10-31 | -7,679,298 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 64,122 | USD | |
| At 2017-10-31 | 60,515 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | -128,592 | USD | 89 |
| 2017-11-01 to 2018-04-30 | -268,213 | USD | 181 |
| 2017-02-01 to 2017-04-30 | -116,834 | USD | 89 |
| 2016-11-01 to 2017-04-30 | -205,422 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 33,814 | USD | |
| At 2017-10-31 | 24,932 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 5,765,292 | USD | |
| At 2017-10-31 | 5,080,474 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | 128,592 | USD | 89 |
| 2017-11-01 to 2018-04-30 | 268,213 | USD | 181 |
| 2017-02-01 to 2017-04-30 | 116,834 | USD | 89 |
| 2016-11-01 to 2017-04-30 | 205,422 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | 7,956 | USD | 89 |
| 2017-11-01 to 2018-04-30 | 23,726 | USD | 181 |
| 2017-02-01 to 2017-04-30 | 12,977 | USD | 89 |
| 2016-11-01 to 2017-04-30 | 27,276 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 69,374,850 | shares | |
| At 2017-10-31 | 69,374,850 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 2,681,261 | USD | |
| At 2017-10-31 | 2,673,620 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | -207,163 | USD | |
| At 2017-10-31 | 9,957 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 511,158 | USD | |
| At 2017-10-31 | 483,482 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-04-30 | 447,036 | USD | |
| At 2017-10-31 | 422,967 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | -208,819 | USD | 89 |
| 2017-11-01 to 2018-04-30 | -431,362 | USD | 181 |
| 2017-02-01 to 2017-04-30 | -183,335 | USD | 89 |
| 2016-11-01 to 2017-04-30 | -337,448 | USD | 181 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | -208,819 | USD | 89 |
| 2017-11-01 to 2018-04-30 | -431,362 | USD | 181 |
| 2017-02-01 to 2017-04-30 | -183,335 | USD | 89 |
| 2016-11-01 to 2017-04-30 | -337,448 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | -170,521 | USD | 89 |
| 2017-11-01 to 2018-04-30 | -648,482 | USD | 181 |
| 2017-02-01 to 2017-04-30 | -175,850 | USD | 89 |
| 2016-11-01 to 2017-04-30 | -271,733 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | 118,298 | USD | 89 |
| 2017-11-01 to 2018-04-30 | 239,970 | USD | 181 |
| 2017-02-01 to 2017-04-30 | 100,238 | USD | 89 |
| 2016-11-01 to 2017-04-30 | 169,861 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-02-01 to 2018-04-30 | 2,338 | USD | 89 |
| 2017-11-01 to 2018-04-30 | 4,517 | USD | 181 |
| 2017-02-01 to 2017-04-30 | 3,619 | USD | 89 |
| 2016-11-01 to 2017-04-30 | 8,285 | USD | 181 |
Inspect the source
- Entity
- Advanced BioMedical Technologies, Inc. / CIK 0001385799
- Captured
- SEC response SHA-256
1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))